CD274 and pancreatic intraductal papillary-mucinous neoplasm: This raises the important question of whether treating high-risk IPMN with anti-PD-1/PD-L1 checkpoint inhibitors could restore immune surveillance and prevent their progression to PDAC (Scheme 1) [60].